Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T14:26:00.315Z.
Calculation as of: 2026-10-06T14:26:00.315Z.
Quote observation: 2026-10-06T14:24:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 77dbea8aa1c4b6afac8bad226ab17e7d6a7ad6f552ac01c17f7c344859946cda
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Caribou Biosciences, Inc.
Market Cap
$116.54M
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | $116.54M | N/A |
| Genelux Corporation (GNLX)vs › | $114.79M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.57M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.83M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $112.36M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $112.52M | N/A |
| BGM Group Ltd. (BGM)vs › | $109.24M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $120.24M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
